Parameter
| Biomarker | BRAF mutations | Full name | B-Raf proto-oncogene, serine/threonine kinase mutations | Molecular Type | Genetic mutations |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Treatment prediction and prognosis | ||
| Disease | Colorectal Cancer (CRC) | Disease Subtypes | / | ||
| Organ | Colorectal | Test Sample / Technology Platform | Tumor tissue/blood (NGS, PCR) | ||
| Pathobiological Mechanisms | BRAF V600E and other mutations activate the MAPK pathway and promote tumor progression, which is associated with poor prognosis and chemotherapy resistance in CRC | ||||
| Clinical Availability Status | Clinical treatment options (available) : as the prognosis of CRC layering and targeted markers for the treatment of choice | ||||
| Notes and Dynamics | CRC patients with BRAF V600E mutation are sensitive to combination therapy with MEK inhibitors, and related drugs have been approved for clinical application | ||||